The firm also announced that it was divesting most of its equity interest in Shanghai Hutchison Pharmaceuticals to invest in its own pipeline.

Patients with advanced lung tumors harboring EGFR exon 19 deletions or exon 21 L858R mutations are eligible for the combo treatment.

The Congressional Budget Office said policies to increase treatment uptake could affect Medicaid, Social Security, and other government programs.

NEW YORK – Carsgen Therapeutics on Monday said it plans to seek approval in China for its autologous CAR T-cell therapy satricabtagene autoleucel (satri-cel) in previously treated patients with ...

The FDA granted priority review to the company's avutometinib-defactinib application and expects to decide on approval in June 2025.

Concr will use data collected by CariGenetics to create AI models to advance precision medicine for triple-negative breast cancer patients in the Caribbean.

Sangamo is seeking new partners to continue advancing giroctocogene fitelparvovec, which reported positive Phase III results this year.

The firm said it plans to share data with regulatory agencies from the Phase III STEER trial after it met its primary endpoint.

Precision Medicine Online readers were interested in stories about implementation challenges in the space, the first cell therapies for solid tumors, and cardiovascular drugs targeting Lp(a).

Regulators approved the first bespoke cell therapies for solid tumors this year, while drugmakers expanded and improved upon ...

The decision follows a similar one in the US and is due to the drug's failure to significantly improve overall survival versus chemo in the TROPION-Lung01 trial.

To be eligible for the firm's half-life extended ImmTAC therapy, patients must be HLA-A*02:01-positive and have advanced solid cancers expressing PRAME.